Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label atomoxetine trial for ADHD in children with 22q11.2 deletion syndrome
2010-024551-82Phase 4Completed
- Sponsor
- King's College London
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by King's College London. Primary endpoint: Primary efficacy endpoint. Started Mar 2011; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2010-024551-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024551-82.